Atlas Trials

A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis

Clinical trial NCT05263817 · UNKNOWN

Trial details

NCT number
NCT05263817
Sponsor
Zhejiang University
Status
UNKNOWN
Phase
Early Phase 1
Study type
INTERVENTIONAL
POEMS SyndromeAmyloidosisAutoimmune Hemolytic AnemiaVasculitis
Start date
2021-10-08
Primary completion
2024-10-01
Enrollment
75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.